DEFINING OUTCOME IN ACUTE STROKE PATIENTS USING BARTHEL INDEX AND MODIFIED RANKIN SCALE TREATED WITH NEUROPROTECTIVE AGENTS

INDER PAL SINGH; KAMALDEEP KAUR; LOVLEEN BHATIA; AJAY PAL

doi:10.22159/ajpcr.2021.v14i8.40959

Authors

INDER PAL SINGH Department of Medicine, Government Medical College, Patiala, Punjab, India.
KAMALDEEP KAUR Department of Medicine, Government Medical College, Patiala, Punjab, India.
LOVLEEN BHATIA Department of Medicine, Government Medical College, Patiala, Punjab, India.
AJAY PAL Department of Medicine, Government Medical College, Patiala, Punjab, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i8.40959

Keywords:

Stroke, Barthel index, Modified Rankin scale

Abstract

Objective: The present study was carried out to describe outcome in acute stroke patients by means of Barthel index (BI) and modified Rankin scale (mRS) treated with neuroprotective agents.

Methods: One hundred acute stroke patients were divided into two groups. Group I patients were treated with citicoline as neuroprotective agent and Group II patients were treated with cerebroprotein hydrolysate as neuroprotective agent. BI and mRS were applied at 1st, 3rd, 6th and 12th week respectively.

Results: The mean BI at 1st week in Group I was 35.3 and in Group II was 36.2, at 3rd week was 50.5 in Group I and 50.1 in Group II, at 6th week was 61.4 in Group I and 59.8 in Group II and at 12th week was 65.8 in Group I and 64.2 in Group II. The difference was non-significant (p>0.05). The mean mRS at 1st week in Group I was 4.5 and in Group II was 4.2, at 3rd week was 3.6 in Group I and 3.9 in Group II, at 6th week was 3.1 in Group I and 3.6 in Group II and at 12th week was 2.5 in Group I and 2.1 in Group II. The difference was non-significant (p>0.05).

Conclusion: A correlation between BI and mRS from baseline to end of 12 weeks within each group was highly significant.

Downloads

Download data is not yet available.

Author Biographies

LOVLEEN BHATIA, Department of Medicine, Government Medical College, Patiala, Punjab, India.

Professor, Department of Medicine

G.M.C. Patiala

AJAY PAL, Department of Medicine, Government Medical College, Patiala, Punjab, India.

Senior Resident, Department of Medicine,

GMC Patiala

References

Grotta J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian lubeluzole ischemic stroke study group. Stroke 1997;28:2338-46.

Diener HC. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 1998;8:172-81.

Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment. ASSIST Steering Committed. Lancet 1997;349:32.

Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 1998;29:12-7.

Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.

Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial. The publications committee for the trial of ORG 10172 in acute stroke treatment (TOAST) investigators. JAMA 1998;279:1265-72.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.

Hacke W, Kaste M, Fiechi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998;352:1245-51.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.

Multicenter Acute Stroke Trial-Europe Study Group, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.

Sulter G, Steen C, de Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-41.

Mehta A, Mahale R, Buddaraju K, Javali M, Acharya P, Srinivasa R. Efficacy of neuroprotective drugs in acute ischemic stroke: Is it helpful? J Neurosci Rural Pract 2019;10:576-81.